With Novavax vaccine deal under its belt, SK Bioscience plots out March IPO on the Korean exchange
It pays to be in the Covid-19 vaccine manufacturing business.
Shortly after it announced an expanded deal to produce 40 million doses of Novavax’s Covid-19 jab, SK Bioscience, an offshoot of Korea’s SK Group, unveiled plans to launch an initial public offering on the Korean Exchange in March with the goal of expanding its contract manufacturing business and building on existing vaccine development platforms.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.